Friday, November 16, 2018 Oslo, Norway, 16 November 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen ... read more

Brussels (Belgium), 15 November 2018, 7:30 AM CET Camel-IDS is developing new radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer Funding will be used for a phase Ib/II trial of the lead program C... read more

GAITHERSBURG, Md., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended September 30, 2018. Recent Corporate Highlights Raised gross proceeds of $41.9 millionÂ... read more

Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial of First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation San... read more

Mölndal, November 8, 2018 – Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the third quarter 2018. Important events during the third quarter In July, Vicore announced it had entered into an agreement to acquire INIM, a Swedish biopharmaceutical company devel... read more